Spero licenses Innovent immune drug in deal worth up to $1.1 billion

• IBI355 targets CD40L protein for autoimmune and inflammatory diseases, with completed early-stage testing in healthy volunteers and Sjögren's disease patients
• Spero plans to begin a mid-stage trial for IgG4-related disease in Q2 2027, while Innovent will conduct a China study in Sjögren's disease by early 2027
• Innovent is eligible for approximately $1.1 billion in total payments including upfront, development, regulatory and commercial milestones, plus sales royalties

Summary

Key Transaction Details:

Spero Therapeutics has acquired exclusive licensing rights to develop and commercialize Innovent Biologics' experimental autoimmune disease treatment IBI355 in territories outside Greater China. The deal carries a total value of up to $1.1 billion, including upfront payments, development milestones, regulatory approvals, commercial milestones, and sales royalties. Innovent retains all rights within its home market of Greater China.

Companies and Strategic Implications:

This transaction marks a significant strategic expansion for Spero Therapeutics, providing the company its first immunology asset as it diversifies beyond its core infectious disease business. For Innovent Biologics, the deal enables global market access while maintaining domestic control.

Drug Profile and Development Timeline:

IBI355 targets CD40L, a protein critical to immune system signaling, and is being developed for autoimmune and inflammatory diseases. The drug has completed early-stage testing in healthy volunteers and initial patient studies in Sjögren's disease. Spero plans to initiate a mid-stage trial for IgG4-related disease in Q2 2027, while Innovent will conduct a separate mid-stage study in China for Sjögren's disease by early 2027.

Target Indications:

• IgG4-related disease: A chronic inflammatory disorder affecting multiple organs
• Sjögren's disease: An autoimmune condition primarily impacting tear and salivary glands

Market Implications:

The substantial deal value reflects growing investor interest in novel autoimmune therapies, particularly those targeting alternative pathways like CD40L. The agreement demonstrates continued appetite for licensing transactions in the biotech sector and China-based innovation gaining global recognition.